Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

Original Research



Precision Cut Cancer Tissue Slices in Anti-Cancer Drug Testing

Florian T Unger, Susanne Bentz, Jana Krüger, Cordula Rosenbrock, Janina Schaller, Katja Pursche, Annika Sprüssel, Hartmut Juhl, Kerstin A David.


Warning: mysql_num_rows() expects parameter 1 to be resource, boolean given in /home2/bibliomed/depo/functions_site.php on line 126

Cited by (1)

Abstract
Background: To meet the urgent need to predict individual drug responses of patients and thus support drug development, better preclinical models of solid tumors are inevitable. Here, a newly developed precision cut cancer tissue slice culture is presented and its use in drug testing was evaluated. Methods: Efficacy of therapeutic compounds from different classes, i.e. Staurosporine, IRESSATM, and Herceptin® was tested within the drug testing platform using fresh precision cut cancer slices from human colon, lung, or breast tumor tissues. The stability and significance of the model were evaluated on the level of gene expression, by antibody diffusion assays, and drug responses were detected by immunohistochemical staining, Meso Scale Discovery (Akt, pAkt) analysis, Western blotting (pAkt, pMAPK), viability (ATP) and apoptosis assays (Caspase-3/7). Results: We obtained sufficient numbers of tissue slices from cancer specimens to be able to perform a wide range of experiments for each individual tumor. In our culture system, cells remained viable and proliferated for at least 4 days within their tissue environment. Viability of tissue slices decreased significantly due to therapeutic treatment in a dose-dependent manner. Gene expression varied remarkably in primary cultivated cells and HT-29 cells in comparison to cultivated tumor slices, which closely represent freshly isolated tumor tissue. An Alexa Fluor 488-labelled antibody showed diffusion in deeper cell layers and the ability of the system to evaluate effects of antibody therapy. Sustained viability of the precision cut cancer tissue slices over 72h enabled to test different drugs. Staurosporine, IRESSATM, and Herceptin® showed a dose-dependent reduction of viability and downstream signaling pathways like Akt and MAPK kinase phosphorylation in EGFR- or Her-2-positive Caco-2 or BT-474 cells or tissue slices, respectively. No effect was seen in EGFR- or Her-2-negative cells and tissues. Conclusions: We showed that this preclinical model is applicable to examine the effects of various anti-cancer compounds like cytotoxic chemotherapeutic drugs as well as targeted therapeutics. It may therefore have significant impact on drug development and patient selection for initial clinical trials.

Key words: Precision cut cancer tissue slices, primary cells, drug testing, 3D culture, chemotherapeutics, IRESSATM, Herceptin®



Full-text options

Full-text Article



Readers of this article also read the following articles
»Cultural Differences in Pain Experience among Four Ethnic Groups: A Qualitative Pilot Study
»Stevia, ka'a he'e, wild sweet herb from South America - An overview
»AO external fixator in the management of open fracture of tibia
»Medication related dystonic reactions especially in children on risperidone: a description of eleven cases and review of the literature
»Anophtalmia/ microphthalmia, a rare congenital anomaly: A case report
»Determining Hepatitis C virus genotype distribution of Amasya area
»Needle stick injuries among health care workers in tertiary care hospital in tertiary care hospital of rural India
»Pityriasis Lichenoides et Varioliformis Acuta (PLEVA): case report
»Study of cord blood ischemia modified albumin levels in the evaluation of birth asphyxia
»Morphological Characteristics of Hassawi Donkey, Eastern Province, Saudi Arabia
»Extending the khalil stage of ?Khesab? dates using new method of packaging and modified calcium formation



Advertisement
Applied Medical Research

SUBMIT YOUR ARTICLE NOW




ScopeMed.com
BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.